Wakabayashi, Y., Masuda, T., Fujitaka, K., Nakashima, T., Okumoto, J., Shimoji, K., . . . Hattori, N. (2020). Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non‐small cell lung cancer. Cancer Sci.
Dyfyniad Arddull ChicagoWakabayashi, Yu, et al. "Clinical Significance of BIM Deletion Polymorphism in Chemoradiotherapy for Non‐small Cell Lung Cancer." Cancer Sci 2020.
Dyfyniad MLAWakabayashi, Yu, et al. "Clinical Significance of BIM Deletion Polymorphism in Chemoradiotherapy for Non‐small Cell Lung Cancer." Cancer Sci 2020.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.